Respiratorius AB (publ) (NGM: RESP)

Sweden flag Sweden · Delayed Price · Currency is SEK
6.50
-0.50 (-7.14%)
At close: Dec 20, 2024
-75.00%
Market Cap 40.02M
Revenue (ttm) n/a
Net Income (ttm) -8.15M
Shares Out 5.10M
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,080
Open 7.25
Previous Close 7.00
Day's Range 6.30 - 7.65
52-Week Range 3.56 - 33.00
Beta 1.67
Analysts n/a
Price Target n/a
Earnings Date Feb 11, 2025

About Respiratorius AB

Respiratorius AB (publ), a research company, develops drug candidates for the treatment of cancer, chronic obstructive pulmonary disease (COPD), and asthma. The company’s products under development include VAL001, which has completed Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden. [Read more]

Industry Other
Founded 1998
Employees 1
Stock Exchange Nordic Growth Market
Ticker Symbol RESP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.